The Nanocovax vaccine of Vietnam produced very good immunity to Covid-19
After a period of clinical trials on humans, vaccine Nanocovax gave very good immunity after the second dose and completely safe for volunteers. The results were analyzed from blood samples from volunteers on 7, 14 and 21 days after injection. In addition to assess the durability and duration of antibodies, the team needs to monitor the volunteers' situation for another 6 months to 1 year.
The above research data is being processed for reporting to the Ministry of Health, and Nanocovax is also determining the appropriate injection dosage for phase 2. It is known that phase 2 will start right after the Lunar New Year. Stage 2 plans to inject over 560 people with more extensive criteria.
The Military Medical Academy also gave a second dose of 25 mcg to three volunteers, two men and one woman, aged 25 to 42. On December 17, 2020, they received the first dose. On the same day, 10 other people were also given a 75 mcg injection, one day earlier than originally planned. These people are currently under close medical monitoring by doctors.
Nanocovax is the first Covid-19 vaccine to be put into human trials, the vaccine was developed by Nanogen Company since May 2020. To date, the first stage vaccine clinical study has gone 50%. The first 60 people received the Nanocovax test injection, with 20 people each.
- Group of 25 mcg: all volunteers received the first dose. Today the first three people received a second dose.
- Group of 50 mcg: all volunteers received the first dose, not the second dose.
- Group of 75 mcg: 13 people received the first dose and are monitoring after injection. The remaining 7 people, scheduled for injection on January 15.